Gilead Sciences (NASDAQ:GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention ...
The National Agency for the Control of AIDS (NACA), on Wednesday, lamented that Ogun State, despite efforts to reduce the ...
Westport failed to provide a resident medication to treat advanced HIV for three weeks, resulting in "significant medication ...
Africa, which is home to roughly two-thirds of people living with HIV, is poised to surpass Asia as the continent with the ...
Although sexually transmitted infections are still at an epidemic level in the US, scientists at the US Centers for Disease ...
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...
The number of sexually transmitted infections (STI) in the United States in 2023 was down nearly 2% from the year before, a ...
Madagascar may soon face an explosion in the incidence of HIV, similar to what it was in southern Africa, TASS reports with ...
according to a report by the agency. The findings provide a “glimmer of hope” that the “tide is turning” after nearly two ...
Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.
(HealthDay News) — The supply of health care professionals available to provide HIV care is expected to continue to decline over the next 5 years, according to research published in the ...
Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...